Rhumbline Advisers Dice Therapeutics, Inc. Transaction History

Rhumbline Advisers

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	SELL	$25.86 - $46.71 $25,316 - $45,729	-979 Reduced 1.8%	53,286 $2.48 Million
Q1 2023 May 11, 2023	BUY	$26.05 - $32.31 $69,683 - $86,429	2,675 Added 5.19%	54,265 $1.56 Million
Q4 2022 Feb 14, 2023	BUY	$19.77 - $42.23 $179,887 - $384,250	9,099 Added 21.41%	51,590 $1.61 Million
Q3 2022 Nov 10, 2022	BUY	$14.97 - $22.65 $36,960 - $55,922	2,469 Added 6.17%	42,491 $862,000
Q2 2022 Aug 11, 2022	BUY	$13.19 - $22.1 $335,448 - $562,047	25,432 Added 174.31%	40,022 $621,000
Q1 2022 May 12, 2022	BUY	$14.54 - $25.02 $61,911 - $106,535	4,258 Added 41.21%	14,590 $279,000
Q4 2021 Feb 10, 2022	BUY	$22.41 - $37.54 $231,540 - $387,863	10,332 New	10,332 $262,000

17.7K

13K

Ticker DICE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,430,000
Description
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lea...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.